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Abstract
Background: Experimental studies demonstrate beneficial immunological and hemodynamic effects of estradiol in
animal models of sepsis. This raises the question whether estradiol contributes to sex differences in the incidence
and outcomes of sepsis in humans. Yet, total estradiol levels are elevated in sepsis patients, particularly nonsurvivors.
Bioavailable estradiol concentrations have not previously been reported in septic patients. The bioavailable estradiol
concentration accounts for aberrations in estradiol carrier protein concentrations that could produce discrepancies
between total and bioavailable estradiol levels. We hypothesized that bioavailable estradiol levels are low in septic
patients and sepsis nonsurvivors.
Methods: We conducted a combined case-control and prospective cohort study. Venous blood samples were obtained
from 131 critically ill septic patients in the medical and surgical intensive care units at the University of Rochester Medical
Center and 51 control subjects without acute illness. Serum bioavailable estradiol concentrations were calculated using
measurements of total estradiol, sex hormone-binding globulin, and albumin. Comparisons were made between patients
with severe sepsis and control subjects and between hospital survivors and nonsurvivors. Multivariable logistic regression
analysis was also performed.
Results: Bioavailable estradiol concentrations were significantly higher in sepsis patients than in control
subjects (211 [78–675] pM vs. 100 [78–142] pM, p < 0.01) and in sepsis nonsurvivors than in survivors (312 [164–918] pM
vs. 167 [70–566] pM, p= 0.04). After adjustment for age and comorbidities, patients with bioavailable estradiol levels above
the median value had significantly higher risk of hospital mortality (OR 4.27, 95 % CI 1.65–11.06, p= 0.003). Bioavailable
estradiol levels were directly correlated with severity of illness and did not differ between men and women.
Conclusions: Contrary to our hypothesis, bioavailable estradiol levels were elevated in sepsis patients, particularly
nonsurvivors, and were independently associated with mortality. Whether estradiol’s effects are harmful, beneficial, or
neutral in septic patients remains unknown, but our findings raise caution about estradiol’s therapeutic potential in this
setting. Our findings do not provide an explanation for sex-based differences in sepsis incidence and outcomes.
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Background
Epidemiological studies show that sex influences both
the incidence and the outcomes of sepsis syndrome.
While the incidence of sepsis appears to be higher in
men [1], some studies paradoxically suggest that sepsis
mortality may be higher in women [2, 3]. The mecha-
nisms for these epidemiological differences are unclear,
but potential explanations include sex differences in
clinical illness presentation, care delivery, or biological
factors, including possible effects of sex hormones [2–4].
Estrogens have protective effects in animal models of
sepsis [5, 6]. For example, sepsis mortality was lower in
proestrus female rats than in males and ovariectomized
females [6] and than in rats receiving an estrogen recep-
tor agonist [7]. These findings might be explained by
several possible salutary effects of estrogen, including
downregulation of proinflammatory cytokines [8–10],
augmentation of vital organ blood flow [11], improved
cardiac contractility [7], and lower production of reactive
oxygen species [11]. In contrast, clinical studies demon-
strate that estrogen concentrations are elevated in critic-
ally ill patients and that higher levels are associated with
poor outcomes [12–14]. Interestingly, blood estrogen
concentrations in critically ill patients are determined
primarily by peripheral fat androgen aromatization [15]
and do not differ significantly by sex [12, 14].
Most previous clinical studies of estrogen levels in crit-
ical illness have included a wide array of intensive care
unit (ICU) patients with and without infection. Ideally,
relationships between estrogen and sepsis should include
an exclusively septic study group because the initial
cytokine cascade and metabolic derangements of sepsis
may be unique [16]. Angstwurm and colleagues focused
on infected ICU patients and observed higher total es-
tradiol levels in nonsurvivors than in survivors [14].
However, it is unknown whether this association
between estradiol concentrations and mortality is con-
founded by potentially important covariables. Most im-
portantly, sepsis-associated alterations in estradiol
carrier protein concentrations could permit high total
yet paradoxically low bioactive hormone concentrations
in nonsurvivors. This is possible because circulating
estradiol binds to albumin and sex hormone-binding
globulin (SHBG). Hormone that is bound to SHBG is in-
active because it is not readily accessible to target tissues
[17]. Malnutrition is associated with elevated SHBG
levels [18] and is a common feature of critical illness
[19]. The bioavailable fraction of circulating total estra-
diol is the sum of the free, unbound, and albumin-
bound fractions. Albumin concentrations decline in
critical illness and are negatively correlated with patient
mortality [20]. Therefore, if sepsis causes relatively low
albumin and high SHBG concentrations, septic patients
could have high total but low bioavailable estradiol
levels. Such alterations in estradiol carrier proteins
would confound the association between high total
estradiol levels and mortality.
To our knowledge, concentrations of the bioavailable
fraction of circulating estradiol have not been reported
previously in septic patients. The aim of this study was
to determine the bioavailable fractions of estradiol in
blood obtained from septic ICU patients. We also aimed
to evaluate relationships between bioavailable estradiol
and mortality after adjusting for common clinical con-
founding variables. We hypothesized that bioavailable
estradiol concentrations would be low in critically ill
septic patients and that low bioavailable estradiol con-
centrations would be associated with higher mortality.
Methods
Study design
This combined cohort and case-control study has been
described previously [21–23]. Consecutive patients in
the medical or surgical ICU of the University of Rochester
Medical Center meeting the 1991 and 2003 consensus
conference criteria for severe sepsis [24] were screened for
enrollment between 2006 and 2009. The inclusion criteria
were (1) having a known or suspected source of infection,
(2) meeting two or more systemic inflammatory response
syndrome criteria, and (3) having one or more acute organ
dysfunctions (for definitions, see Additional file 1: Table
S2). Control subjects without acute illness were recruited
from the local community and stratified by age and sex to
approximate the sepsis cohort. A list of all prospectively
defined exclusion criteria is shown in Fig. 1. We also could
not enroll eligible patients if research staffing was inad-
equate to obtain and process blood specimens within 48 h
after patients fulfilled severe sepsis criteria. Written
informed consent was obtained from all subjects or their
surrogates, and the study protocol was approved by the
University of Rochester Research Subjects Review Board.
Measurement of estradiol levels
Venous blood samples were obtained within 48 h of a
patient’s fulfilling severe sepsis criteria. A second venous
blood sample was collected 72–96 h after the first sam-
ple in the remaining patients. Serum samples dedicated
to these hormone measurements were stored continu-
ously at −80 °C until analysis. Commercially available
kits were used to measure serum concentrations of
SHBG (enzyme immunoassay; ALPCO, Salem, NH,
USA), estradiol (radioimmunoassay; Diagnostic Systems
Laboratories, Webster, TX, USA), and plasma albumin
(QuantiChrom™ BCG Albumin Assay Kit; BioAssay
Systems, Hayward, CA, USA). All samples were measured
in duplicate. The free and albumin-bound serum estradiol
concentrations were calculated as previously described
(see supplementary methods in Additional file 1) [25–28].
Tsang et al. Critical Care  (2016) 20:335 Page 2 of 8
The bioavailable estradiol concentration was calculated as
the sum of the free and albumin-bound estradiol concen-
trations [26, 28]. All laboratory measurements were com-
pleted by April 2010.
Statistical analysis
Estradiol levels had a skewed distribution, so nonpara-
metric Mann-Whitney U and Wilcoxon signed-rank
tests were used to compare groups. The results are
expressed as median (interquartile range). Spearman’s
rank correlation coefficients (rho) were calculated be-
tween bioavailable estradiol concentration and other
continuous severity of illness variables, including Acute
Physiology and Chronic Health Evaluation II scores [29],
Sepsis-related Organ Failure Assessment (SOFA) scores
[30], and the number of organ failure-free days from
days 0 to 28 [31].
Multivariable logistic regression was used to assess the
independent association between high bioavailable estra-
diol concentrations (above the median value in sepsis
patients) and hospital mortality. Age, sex, and Charlson
comorbidity index [32] were clinically judged to be po-
tentially important confounding variables and were
therefore included in the base multivariable model.
Covariables were sequentially removed if comparisons
between the nested model and the base model were in-
significant (p ≥ 0.10 by likelihood ratio test), beginning
with the covariable least associated with the outcome
variable and continuing in order until a covariable’s re-
moval caused deterioration in the model fit (p < 0.10 by
likelihood ratio test). Bioavailable estradiol concentration
was then introduced into the parsimonious model. Stat-
istical analyses were performed using SAS version 9.1.3
software (SAS Institute, Cary, NC, USA) and Stata 12
software (StataCorp, College Station, TX, USA). Results
were considered statistically significant if p ≤ 0.05, unless
otherwise specified.
Results
Between February 2006 and February 2009, 52 healthy
volunteers and 139 sepsis patients were enrolled in the
study (Fig. 1). Serum sample volumes were insufficient
in one healthy volunteer and eight sepsis patients. These
subjects were removed from further analysis. At the time
of the second hormone measurement, 21 sepsis patients
had missing hormone data because of death (n = 11),
hospital discharge (n = 4), or insufficient sample (n = 6).
Baseline demographics for the healthy volunteer and
sepsis patient cohorts are shown in Table 1.
Consistent with prior studies, sepsis patients had sig-
nificantly higher total estradiol concentrations than
healthy control subjects (Table 2). Sepsis patients had
lower albumin concentrations and higher SHBG concen-
trations than control subjects. These differences in estra-
diol carrier proteins would be expected to diminish the
bioavailable estradiol fraction in septic patients, consist-
ent with our original hypothesis. Nevertheless, bioavail-
able estradiol concentrations were still higher in sepsis
patients than in control subjects (Table 2 and Fig. 2).
Thirty-three (25 %) of the sepsis patients died during
hospitalization (see Table 1 for comparison of clinical
characteristics between survivors and nonsurvivors).
Total and bioavailable estradiol concentrations were
significantly higher in nonsurvivors than in survivors
(Table 2 and Fig. 3). Albumin was lower among nonsur-
vivors, while SHBG was similar between the two groups
Fig. 1 Enrollment algorithm for patients with severe sepsis
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(Table 2). The final multivariable model included age
and Charlson comorbidity index. After adjustment for
these covariables, patients with higher bioavailable levels
had a significantly higher likelihood of dying in the hos-
pital than did those with concentrations less than or
equal to the median value (OR 4.27, 95 % CI 1.65–11.06,
p = 0.003) (Table 3).
Bioavailable estradiol was positively correlated with
7-day maximum and mean SOFA scores (Spearman’s
rho = 0.28 and p < 0.01 for both) and negatively correlated
with the number of organ failure-free days from days
0–28 (Spearman’s rho = −0.26, p < 0.01). Bioavailable
estradiol concentrations decreased over time in the sepsis
patients (see Additional file 1: Table S2). Estradiol
Table 1 Clinical characteristics of study subjects
Controls (n = 51) Sepsis (n = 131) p Value Survivors (n = 98) Nonsurvivors (n = 33) p Value
Age, years 60 (53–66) 62 (48–74) 0.65 57 (47–69) 71 (61–78) <0.01
Male sex 26 (51 %) 75 (57 %) 0.45 56 (57 %) 19 (58 %) 0.97
Race 0.23 0.09
White 48 (94 %) 108 (82 %) 81 (83 %) 27 (82 %)
African American 3 (6 %) 20 (15 %) 16 (16 %) 4 (12 %)
Asian 0 1 (1 %) 1 (1 %) 0
Hispanic/Latino 0 2 (2 %) 0 2 (6 %)
Charlson comorbidity index [32] 0 (0–1) 3 (1–6) <0.01 2 (1–5) 4 (3–8) <0.01
Admission type – 0.01
Medical patient – 118 (90 %) 92 (78 %) 26 (22 %)
Surgical patient – 13 (10 %) 6 (46 %) 7 (54 %)
Site of infection – 0.74
Pulmonary – 76 (58 %) 54 (55 %) 22 (67 %)
Intra-abdominal – 19 (15 %) 14 (14 %) 5 (15 %)
Urinary – 15 (11 %) 13 (13 %) 2 (6 %)
Skin/catheter – 6 (5 %) 5 (5 %) 1 (3 %)
Other – 15 (11 %) 12 (12 %) 3 (9 %)
Microbiology – 0.34
Gram-positive bacteria – 42 (32 %) 30 (31 %) 12 (36 %)
Gram-negative bacteria – 20 (15 %) 15 (15 %) 5 (2 %)
Fungal – 3 (2 %) 3 (3 %) 0
Mixed or other – 27 (21 %) 17 (17 %) 10 (30 %)
Unknown – 39 (30 %) 33 (34 %) 6 (2 %)
Positive blood culture – 48 (37 %) – 36 (37 %) 12 (36 %) 0.97
Septic shocka – 107 (82 %) – 75 (77 %) 32 (97 %) 0.01
APACHE II score – 24 ± 9 – 22 ± 8 30 ± 9 <0.01
SOFA scoreb
Minimum – 7 (5–9) – 6 (4–8) 11 (8–12) <0.01
Maximum – 10 (8–13) – 9 (8–11) 13 (11–16) <0.01
Mean – 8 (6–11) – 8 (6–9) 12 (9–14) <0.01
ICU LOS, days – 6 (3–12) – 6 (3–11) 8 (3–17) 0.21
Hospital LOS, days – 15 (9–29) 14 (9–26) 15 (7–39) 0.43
Ventilator-free days 0–28c – 21 (3–28) – 24 (20–28) 0 (0–0) <0.01
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II [29], SOFA Sepsis-related Organ Failure Assessment, LOS Length of stay, ICU Intensive
care unit
Values are median (interquartile range), number (percentage), or mean ± SD
aShock was defined as hypotension or vasopressor dependence that persisted for ≥3 h despite fluid challenge at the time of diagnosis
bDaily SOFA scores were calculated. Values refer to the minimum, maximum, and mean SOFA scores from the day of diagnosis through day 7
cVentilator-free days 0–28 represent the number of days free of ventilator support from the day of diagnosis through day 28
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concentrations did not differ between men and women
(see Additional file 1: Table S3).
Discussion
The main findings of our study are that bioavailable
estradiol levels are elevated in critically ill septic patients
compared with healthy controls and in sepsis nonsurvi-
vors compared with survivors. While confirming previ-
ous observations, our study uniquely demonstrates that
the higher estradiol levels characterizing sepsis are in the
biologically active pool and are not an artifact of sepsis-
associated alterations in carrier protein concentrations.
Furthermore, we found that patients with particularly
high bioavailable estradiol levels had a higher risk of
death even when we adjusted for potential confounding
variables. Finally, higher bioavailable estradiol levels are
also linked to higher severity of illness.
We hypothesized that higher bioavailable estradiol
concentrations would be associated with lower mortality
in septic patients. This hypothesis was driven by labora-
tory studies suggesting a therapeutic benefit from
estrogens. For example, in rodents undergoing cecal
ligation and puncture, mortality was lower in proestrus
females than in ovariectomized females or in males [6].
Furthermore, treatment with an estrogen receptor agon-
ist improved survival in this animal model [7]. Our
contradictory findings highlight the limitations of obser-
vational clinical research: It is capable of detecting
clinical associations but incapable of demonstrating
causality or pathophysiological significance. In this case,
for example, higher bioavailable estradiol levels in sepsis
nonsurvivors do not necessarily indicate a deleterious
excess. If estradiol has beneficial biological effects, our
findings could represent an adaptive but insufficient
response to sepsis, diminished receptor sensitivity, or
both. Alternatively, bioavailable estradiol may simply be
an acute-phase reactant without pathophysiological
significance. Finally, it is possible that bioavailable estra-
diol has adverse pathological effects, with higher levels
promoting adverse sepsis outcomes. Unfortunately, our
findings do not allow us to draw any inference about
which of these three possibilities is operative.
Comparison with previous literature
Several studies have shown that elevated total estradiol
levels are linked to mortality in both noninfected and in-
fected critically ill patients [12–14, 33–35]. Our findings
are consistent with these prior results and extend them
Table 2 Estradiol and carrier protein concentrations
Control subjects vs. sepsis patients Sepsis, survivors vs. nonsurvivors
Variable Controls (n = 51) Sepsis (n = 131) p Value Survivors (n = 98) Nonsurvivors (n = 33) p Value
Total estradiol, pM 115 (88–166) 275 (112–916) <0.01 222 (100–814) 512 (276–1040) 0.01
Albumin-bound estradiol, pM 97 (76–139) 199 (74–637) <0.01 156 (66–538) 278 (154–855) 0.04
Free estradiol, pM 3 (2–4) 10 (4–46) <0.01 8 (4–28) 23 (10–73) <0.01
Bioavailable estradiol, pM 100 (78–142) 211 (78–675) <0.01 167 (70–566) 312 (164–918) 0.04
Albumin, g/dl 5.24 (4.61–5.71) 2.67 (2.06–3.49) <0.01 3.00 (2.30–3.74) 2.06 (1.72–2.63) <0.01
SHBG, nM 9.52 (4.13–22.06) 19.00 (10.50–32.80) <0.01 19.00 (11.20–32.50) 17.41 (7.92–34.19) 0.70
SHBG Sex hormone-binding globulin
Values are given as median (interquartile range)
Fig. 2 Bioavailable estradiol in sepsis patients versus control subjects.
Box plot shows the medians with 25th and 75th percentiles. The circles
represent outliers beyond the whiskers that designate the 10th and
90th percentiles
Fig. 3 Bioavailable estradiol in sepsis survivors versus nonsurvivors.
Box plot shows medians with 25th and 75th percentiles. The circles
represent outliers beyond the whiskers that designate the 10th and
90th percentiles
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by demonstrating that the bioavailable estradiol fraction
is also elevated in sepsis and sepsis nonsurvivors. By
calculating the bioavailable estradiol concentration, we
found that associations between estradiol and sepsis, and
between estradiol and sepsis mortality, persist after con-
trolling for the changes in carrier proteins that occur in
critical illness. To our knowledge, this has not been
reported previously.
The influence of sex
We found that bioavailable estradiol concentration did
not vary by sex. These findings are consistent with previ-
ous reports that total estradiol did not significantly differ
between critically ill men and women [12–14, 33, 36].
Despite these similarities in hormone levels, recent, large
sepsis epidemiological studies indicate that sepsis mortal-
ity varies by sex [37–39]. Together, these results suggest
that sex differences in mortality are not mediated by hor-
monal effects. Other possible mechanisms need to be con-
sidered, including sex differences in care delivery [2–4].
Strengths and limitations
The strengths of our study are its prospective design and
inclusion of the measurements necessary for calculation
of bioavailable estradiol. Our study has several limita-
tions. First, its observational design precludes estab-
lishment of a causal relationship between bioavailable
estradiol concentrations and sepsis or mortality.
Second, we were unable to investigate relationships
between estradiol, inflammation, and physiological
stress because we did not measure markers of the
inflammatory and stress responses. Third, our samples
were obtained a median of 27 h after patients met
diagnostic criteria, and the results may have been dif-
ferent if samples had been obtained earlier. Third, we
cannot determine if our findings are unique to sepsis
or characterize critical illness more generally. Finally,
our inclusion criteria were based on prior sepsis syn-
drome definitions that have since been updated [40].
Nevertheless, all patients had known or suspected in-
fection and SOFA scores >2 (Table 1), indicating that
they also satisfied the latest revised sepsis criteria.
Conclusions
The serum bioavailable estradiol concentration is signifi-
cantly elevated in critically ill septic patients compared
with healthy control subjects of similar age and sex
distribution. Further, high bioavailable estradiol levels in-
dependently predict mortality in sepsis. Bioavailable
estradiol levels were similar in septic men and women.
Our results do not provide an explanation for previously
documented sex differences in sepsis outcomes, and
more research is warranted to explore these differences.
Additional study is also required to establish whether
estradiol’s predominant effects in sepsis are deleterious,
beneficial, or neutral.
Key messages
 The bioavailable fraction of circulating estradiol is
high in sepsis and is not affected by sex.
 Nonsurvivors have higher bioavailable estradiol
levels than survivors, and higher levels are
independently associated with hospital mortality.
Additional file
Additional file 1: Table S1. Inclusion criteria. Table S2. Measurement 1
vs. measurement 2 in survivors and nonsurvivors. Table S3.
Concentrations of estradiol and carrier proteins by gender. (DOCX 35 kb)
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